<DOC>
	<DOC>NCT00911092</DOC>
	<brief_summary>The scope of the trial is to predict the early complete clinical response to exclusive concomitant radiochemotherapy in esophageal cancer by the study of the pre- and per- therapeutic proteomic profile.</brief_summary>
	<brief_title>Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer</brief_title>
	<detailed_description>Further informations will be provided by Centre Oscar Lambret.</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Invasive esophageal carcinoma at any stage (all T, N0 or N1, M0 or M1a), histologically proven Treated by exclusive concomitant radiochemotherapy Written informed consent Presence of a second uncontrolled cancer Metastatic carcinoma Metastatic disease, except cervical lymphnodes... (M1a) In situ carcinoma Esogastric junction cancer (Siewert II ou III) Inclusion in a clinical trial with an experimental drug during the study and until 15 weeks after the end of radiotherapy)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Oesophageal cancer</keyword>
	<keyword>exclusive concomitant radiochemotherapy</keyword>
</DOC>